Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy

• Published in: ACS nano Vol. 15; no. 2; pp. 3123 - 3138
• Main Authors: Hu, Mei, Zhang, Jiao, Kong, Li, Yu, Yulin, Hu, Qian, Yang, Ting, Wang, Yi, Tu, Kun, Qiao, Qi, Qin, Xianya, Zhang, Zhiping
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 23.02.2021
• Subjects: Animals; Cell Line, Tumor; Doxorubicin - pharmacology; Drug Delivery Systems; Immunotherapy; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms; hybrid nanovesicles; liposomes; tumor-derived nanovesicles; immunogenic cell death; immunochemotherapy
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.0c09681

Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles (DOX@LINV) via fusing artificial liposomes (LIPs) with tumor-derived nanovesicles (TNVs) for combinational immunochemotherapy. DOX@LINV with a homologous targeting ability could deliver DOX to tumor tissue and elicit an effective immunogenic cell death response to improve the immunogenicity of a tumor. Meanwhile, the preserved tumor antigens and endogenous danger signals in DOX@LINV activated dendritic cells and induced a subsequent antigen-specific T cell immune response. DOX@LINV displayed a specific antitumor effect on murine melanoma, Lewis lung cancer, and 4T1 breast cancer based on the infiltration of effector immune cells and improvement of the immunosuppressive tumor microenvironment. Furthermore, the combination of DOX@LINV with immune checkpoint inhibitor amplified antitumor efficacy with 33.3% of the mice being tumor-free. Therefore, the hybrid LINV is a promising drug delivery platform with a boosted antitumor immune response for effective immunochemotherapy.